Protein Tyrosine Phosphatase

Cat. No.

A36298

CAS No.

150627-37-5

RK-682

RK-682 is a potent inhibitor of protein tyrosine phosphatases (PTPases), targeting specifically the dephosphorylation of CD45 and VHR, with IC50 values of 54 μM and 2.0 μM, respectively. This inhibition disrupts the ERK signaling pathway, leading to significant effects on cancer cell viability with IC50 values of 78.2 nM for MGH-U3, 43.2 nM for T24, and 145 nM for UROtsa. Additionally, RK-682 induces cell cycle arrest at the G1/S phase and suppresses both cell migration and autophagy in MGH-U3 and T24 cell lines, making it a valuable tool for cancer research.

Cat. No.

A36301

CAS No.

132922-80-6

Rubrofusarin 6-O-β-D-glucopyranoside

Rubrofusarin 6-O-β-D-glucopyranoside is a glycoside derivative that acts as a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting an IC50 value of 87.36 μM. This compound plays a significant role in the exploration of the molecular mechanisms associated with comorbid diabetes and depression, making it a valuable tool for relevant biochemical and pharmacological studies.

Cat. No.

A36310

CAS No.

2702673-78-5

PTP1B-IN-3 diammonium

PTP1B-IN-3 diammonium is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 value of 120 nM. This compound effectively targets PTP1B and T cell protein tyrosine phosphatase (TCPTP), making it significant for studies in diabetes and cancer research. Its demonstrated antidiabetic and anticancer activities position PTP1B-IN-3 diammonium as a valuable tool for exploring therapeutic strategies in these diseases.

Cat. No.

A36312

CAS No.

117204-81-6

Sophoraisoflavone A

Synonyms: Allolicoisoflavone B

Sophoraisoflavone A is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting an IC50 value of 0.80 μM. This naturally occurring compound, derived from Glycyrrhiza inflate, is significant for its anti-inflammatory properties. It is valuable for research applications focusing on metabolic disorders and related inflammatory pathways.

Cat. No.

A36319

CAS No.

2848581-85-9

PTP1B-IN-17

PTP1B-IN-17 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting a Ki value of 30.2 μM. This benzimidazole derivative is primarily used in research related to type 2 diabetes, where modulation of PTP1B activity can influence insulin signaling pathways and glucose homeostasis. Its specificity and potency make it a valuable tool for investigating the role of PTP1B in metabolic disorders.

Cat. No.

A36320

CAS No.

853310-63-1

MLS-0322825

MLS-0322825 is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), demonstrating an IC50 of 3.3 μM for LMPTP-A. This compound exhibits remarkable selectivity over other phosphatases, including class I tyrosine-specific lymphoid phosphatase (LYP) and vaccinia H1-related phosphatase (VHR). MLS-0322825 is applicable in research targeting type 2 diabetes and offers a valuable tool for studying LMPTP's role in metabolic pathways.

Cat. No.

A36324

CAS No.

30779-02-3

3-Hydroxyphloridzin

Synonyms: 3-Hydroxyphlorizin

3-Hydroxyphloridzin is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), which plays a critical role in regulating insulin signaling. By modulating the phosphorylation levels of the insulin receptor, 3-Hydroxyphloridzin may enhance insulin sensitivity and has potential applications in the study of type 2 diabetes and related metabolic disorders. This compound is valuable for researchers investigating therapeutic strategies aimed at improving insulin action.

Cat. No.

A36325

CAS No.

332131-32-5

RK-682 hemicalcium

RK-682 hemicalcium is a potent inhibitor of protein tyrosine phosphatases (PTPases), specifically targeting CD45 and VHR, with IC50 values of 54 μM and 2.0 μM, respectively. This compound effectively disrupts the ERK signaling pathway and exhibits significant cytotoxicity in cancer cell lines MGH-U3, T24, and UROtsa, with IC50 values of 78.2 nM, 43.2 nM, and 145 nM, respectively. Additionally, RK-682 hemicalcium induces G1/S phase cell cycle arrest and inhibits cell migration and autophagy, making it a valuable tool for cancer research and therapeutic investigations.

Cat. No.

A36328

CAS No.

83474-71-9

Mulberrofuran D

Mulberrofuran D is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting an IC50 value of 11.61 μM and a Ki of 4.79 μM against human PTP1B. This compound is primarily utilized in research focused on type 2 diabetes, serving as a valuable tool for investigating insulin signaling pathways and potential therapeutic interventions. Its selective inhibition of PTP1B positions Mulberrofuran D as a significant reagent for studying metabolic disorders.

Cat. No.

A36333

CAS No.

1146616-17-2

VHR-IN-7

VHR-IN-7 is a selective inhibitor of the vaccinia H1-related (VHR) phosphatase, demonstrating an IC50 of 71 nM. It exhibits significantly weaker inhibitory effects on other phosphatases, including MKP-1, CD45, Cdc25A, PTP1B, and HePTP. VHR-IN-7 effectively inhibits the proliferation of HeLa cells, making it a valuable tool for research into cervical cancer and related therapeutic strategies.

Cat. No.

A36335

CAS No.

2848581-83-7

PTP1B-IN-19

PTP1B-IN-19 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting an inhibitory constant (Ki) of 23.3 μM. This benzimidazole derivative is primarily utilized in research focused on type 2 diabetes, exploring its role in glucose metabolism and insulin signaling pathways. Its inhibition of PTP1B may contribute to improved insulin sensitivity and offer insights into therapeutic strategies for diabetes management.

Cat. No.

A36336

CAS No.

329975-47-5

(24E)-3,4-Secocucurbita-4,24-diene-3,26,29-trioic acid

(24E)-3,4-Secocucurbita-4,24-diene-3,26,29-trioic acid is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting an IC50 of 0.4 μM. This compound demonstrates significant PTP1B inhibitory activity while maintaining a non-cytotoxic profile. Its selective action makes it an invaluable tool for research focused on insulin signaling and metabolic regulation.

Cat. No.

A36339

CAS No.

2524718-73-6

LXQ-87

LXQ-87 is a noncompetitive inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 of 1.061 μM. This compound exhibits hypoglycemic activity by alleviating insulin resistance and enhancing cellular glucose uptake. LXQ-87 is valuable in research on type 2 diabetes and related metabolic disorders.

Cat. No.

A36351

CAS No.

3001295-81-1

PTP1B-IN-20

PTP1B-IN-20 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), with an IC50 value of 1.05 μM, demonstrating a significant preference over T-cell protein tyrosine phosphatase (TCPTP), which has an IC50 of 78.0 μM. PTP1B plays a crucial role in insulin signaling and glucose homeostasis, making this compound a valuable tool for research in type 2 diabetes and metabolic disorders. Its specificity for PTP1B enables detailed studies on the modulation of this enzyme and its implications in insulin resistance and related diseases.

Cat. No.

A36352

CAS No.

1191105-54-0

VHR-IN-3

VHR-IN-3 is a selective inhibitor of the vaccinia H1-related (VHR) phosphatase, exhibiting a Ki of 0.81 μM. It functions by mimicking the phosphate group through its sulfonic acid moiety, allowing it to competitively bind to the catalytic active site of VHR. This compound is instrumental in research aimed at understanding the role of VHR in cervical cancer and other related biological processes.

Cat. No.

A36353

CAS No.

1908414-82-3

LMPTP inhibitor 1

LMPTP inhibitor 1 is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), demonstrating an IC50 value of 0.8 μM against LMPTP-A. This compound is ideal for studying the role of LMPTP in various cellular processes, including signal transduction and cellular differentiation. It serves as a valuable tool in research focused on cancer biology, neurodegenerative diseases, and metabolic disorders, where LMPTP regulation is crucial for understanding disease mechanisms and therapeutic strategies.

Cat. No.

A36355

CAS No.

154639-24-4

(Rac)-RK-682

(Rac)-RK-682 is a potent inhibitor of protein tyrosine phosphatases (PTPases), specifically targeting protein tyrosine phosphatase 1B (PTP-1B), low molecular weight protein tyrosine phosphatases (LMW-PTP), and cell division cycle 25B (CDC-25B). It exhibits inhibitory activities with IC50 values of 8.6 μM for PTP-1B, 12.4 μM for LMW-PTP, and 0.7 μM for CDC-25B. This compound is valuable for research applications focused on signal transduction pathways and regulation of cellular processes associated with PTPase activity.

Cat. No.

A36358

CAS No.

202815-28-9

Licoagrochalcone A

Licoagrochalcone A is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B). This compound demonstrates protective effects against liver cell injury induced by carbon tetrachloride and acetaminophen, making it valuable for research in metabolic disorders. Licoagrochalcone A is applicable in studies related to type 2 diabetes, obesity, and liver injury, providing insights into potential therapeutic strategies.

Cat. No.

A36359

CAS No.

2701546-87-2

PTP1B-IN-32

PTP1B-IN-32 is an uncompetitive inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting a Ki value of 0.72 μM. This compound plays a crucial role in enhancing insulin sensitivity, making it a valuable tool for studying metabolic disorders. PTP1B-IN-32 is particularly relevant in diabetes research, contributing to the understanding of insulin signaling mechanisms.

Cat. No.

A36361

CAS No.

1146616-16-1

VHR-IN-6

VHR-IN-6 is a selective inhibitor of the vaccinia H1-related (VHR) phosphatase, exhibiting an IC50 of 74 nM. It demonstrates significantly lower inhibitory activity against other phosphatases such as MKP-1, CD45, Cdc25A, PTP1B, and HePTP. VHR-IN-6 effectively inhibits the proliferation of HeLa cells, making it a valuable tool for investigating cervical cancer and related signaling pathways.

Cat. No.

A36362

CAS No.

376362-03-7

1-(4-Hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl)

1-(4-Hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl) is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting an IC50 of 13.00 μM in vitro. PTP1B plays a critical role in regulating insulin signaling and is implicated in the development of insulin resistance and non-insulin-dependent diabetes mellitus. This compound serves as a valuable tool for research into metabolic disorders, particularly in the context of type 2 diabetes therapeutics.

Cat. No.

A36363

CAS No.

3033936-66-9

PTPN2-IN-1

PTPN2-IN-1 is a potent inhibitor of Protein Tyrosine Phosphatase N2 (PTPN2) with an IC50 of ≤5 μM. This compound has demonstrated efficacy in inhibiting cell growth in B16F10 melanoma cells, making it a valuable tool for research in cancer biology. Its specific target engagement provides insights into the regulatory roles of PTPN2 in cellular signaling pathways and potential therapeutic applications.

Cat. No.

A36378

CAS No.

1146616-14-9

VHR-IN-2

VHR-IN-2 is a selective inhibitor of the vaccinia H1-related phosphatase (VHR), demonstrating an IC50 of 3.1 μM. This compound is primarily utilized in research focused on cervical cancer, where VHR plays a significant role in tumor progression and pathology. VHR-IN-2 serves as an important tool for elucidating the biological functions of VHR and exploring its potential as a therapeutic target.

Cat. No.

A36381

CAS No.

2948339-38-4

Anticancer agent 143

Anticancer agent 143 is a dual inhibitor of PTPN2 and PTP1B, demonstrating potent bioactivity with IC50 values of less than 2.5 nM. This compound is valuable for cancer research, providing insights into the roles of these protein tyrosine phosphatases in tumor biology and potential therapeutic strategies.

Cat. No.

A36387

CAS No.

2848581-86-0

PTP1B-IN-16

PTP1B-IN-16 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting a Ki value of 12.6 μM. This benzimidazole derivative is primarily utilized in research focused on type 2 diabetes. By inhibiting PTP1B, this compound may contribute to the modulation of insulin signaling pathways, thereby providing insights into potential therapeutic strategies for metabolic disorders.